Abstract
Large doses of omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are used to treat several diseases including hypertriglyceridemia in humans. Modest levels of EPA and DHA may be obtained from food, particularly from fatty fish. This review presents the literature examining the differences between omega-3 fatty acid dietary supplementation and prescribed omega-3-acid ethyl esters (P-OM3). Reports published between 1995 and 2007 containing sources, recommended intake, and differences in the various formulations of omega-3 fatty acids were sought in PubMed and the Food and Drug Administration (FDA) Websites. However, lack of head-to-head clinical trials using both P-OM3 and dietary-supplement omega-3 fatty acids is the greatest limitation of this review. Although many kinds of omega-3 fatty acid dietary supplements are available, the efficacy, quality, and safety of these products are questionable because they are beyond any pharmaceutical control. Thus, P-OM3 is the only FDA approved omega-3 fatty acid product which is available in the United States as an adjunct to diet to improve human health.
Keywords: Omega-3 fatty acids, diet, supplementation, triglycerides
Current Pharmaceutical Design
Title: PUFA for Human Health: Diet or Supplementation?
Volume: 15 Issue: 36
Author(s): P. Abete, G. Testa, G. Galizia, D. Della-Morte, F. Cacciatore and F. Rengo
Affiliation:
Keywords: Omega-3 fatty acids, diet, supplementation, triglycerides
Abstract: Large doses of omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are used to treat several diseases including hypertriglyceridemia in humans. Modest levels of EPA and DHA may be obtained from food, particularly from fatty fish. This review presents the literature examining the differences between omega-3 fatty acid dietary supplementation and prescribed omega-3-acid ethyl esters (P-OM3). Reports published between 1995 and 2007 containing sources, recommended intake, and differences in the various formulations of omega-3 fatty acids were sought in PubMed and the Food and Drug Administration (FDA) Websites. However, lack of head-to-head clinical trials using both P-OM3 and dietary-supplement omega-3 fatty acids is the greatest limitation of this review. Although many kinds of omega-3 fatty acid dietary supplements are available, the efficacy, quality, and safety of these products are questionable because they are beyond any pharmaceutical control. Thus, P-OM3 is the only FDA approved omega-3 fatty acid product which is available in the United States as an adjunct to diet to improve human health.
Export Options
About this article
Cite this article as:
Abete P., Testa G., Galizia G., Della-Morte D., Cacciatore F. and Rengo F., PUFA for Human Health: Diet or Supplementation?, Current Pharmaceutical Design 2009; 15 (36) . https://dx.doi.org/10.2174/138161209789909665
DOI https://dx.doi.org/10.2174/138161209789909665 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthetic Thioamide, Benzimidazole, Quinolone and Derivatives with Carboxylic Acid and Ester Moieties: A Strategy in the Design of Antituberculosis Agents
Current Medicinal Chemistry Biotransformation of Bioactive Natural Products for Pharmaceutical Lead Compounds
Current Organic Chemistry Effects of High-Fat Diets from Different Sources on Serum and Thymus Lipid Profile: Study in an Experimental Model
Endocrine, Metabolic & Immune Disorders - Drug Targets Pre-procedural Elevated White Blood Cell Count and Neutrophil-Lymphocyte (N/L) Ratio are Predictors of Ventricular Arrhythmias During Percutaneous Coronary Intervention
Cardiovascular & Hematological Disorders-Drug Targets Update on Anti-TNF-Alpha Treatment in Rheumatic Diseases
Current Drug Therapy Pharmacology of Ivabradine and the Effect on Chronic Heart Failure
Current Topics in Medicinal Chemistry The Proteomic Approach in the Development of Prognostic Biomarkers in Atherothrombosis
Recent Patents on Cardiovascular Drug Discovery Genetic Basis, Nutritional Challenges and Adaptive Responses in the Prenatal Origin of Obesity and Type-2 Diabetes
Current Diabetes Reviews A SELDI-TOF-MS Study in Lacunar Stroke with Subsequent Haptoglobin Phenotyping
Current Neurovascular Research Transcription Factors in Heart: Promising Therapeutic Targets in Cardiac Hypertrophy
Current Cardiology Reviews Potential Targets for Intervention in Radiation-Induced Heart Disease
Current Drug Targets Statin Therapy and Cognition in Older People: What is the Evidence?
Current Clinical Pharmacology Periodontitis and Atherosclerosis, a Causal Relationship?
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Receptor-Binding and Pharmacokinetic Properties of Dopaminergic Agonists
Current Topics in Medicinal Chemistry Vitamin D Supplementation for Obesity: Potential Mechanisms of Action and an Update of Randomized Controlled Trials
Current Nutrition & Food Science Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Induced Dyspepsia
Current Pharmaceutical Design Biomarker Discovery in Clinical Proteomics: Strategies for Exposing Low Abundant Proteins
Current Proteomics Recent Advances and Patents on Novel Devices for Minimally Invasive Treatment of Functional Mitral Regurgitation
Recent Patents on Biomedical Engineering (Discontinued) Docking, Synthesis and Anti-Diabetic Activity of Novel Sulfonylhydrazone Derivatives Designed as PPAR-Gamma Agonists
Current Topics in Medicinal Chemistry Acute Antithrombotic Treatment of Ischemic Stroke
Current Vascular Pharmacology